Safety and Efficacy of BARS13 in the Elderly

NCT04681833 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
DRUG: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
DRUG: Placebo

Sponsor

Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.